about
MEF2C exon α: role in gene activation and differentiationValproic acid causes proteasomal degradation of DICER and influences miRNA expressionGenome wide array analysis indicates that an amyotrophic lateral sclerosis mutation of FUS causes an early increase of CAMK2N2 in vitro.The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology.The contribution of the citrate pathway to oxidative stress in Down syndrome.Mitochondrial carriers in inflammation induced by bacterial endotoxin and cytokines.Sudemycin E influences alternative splicing and changes chromatin modifications.Insight into mechanism of in vitro insulin secretion increase induced by antipsychotic clozapine: role of FOXA1 and mitochondrial citrate carrier.2-Aminopyridine derivatives as potential σ(2) receptor antagonists.Transcription of the mitochondrial citrate carrier gene: identification of a silencer and its binding protein ZNF224.Involvement of PARP1 in the regulation of alternative splicingStatins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression.Identification of a novel Sp1 splice variant as a strong transcriptional activator.New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.Permethylated Anigopreissin A inhibits human hepatoma cell proliferation by mitochondria-induced apoptosis.The mitochondrial citrate carrier: a new player in inflammationRole of FOXA and Sp1 in mitochondrial acylcarnitine carrier gene expression in different cell linesTranscriptional Regulation Factors of the Human Mitochondrial Aspartate/Glutamate Carrier Gene, Isoform 2 (): USF1 as Basal Factor and FOXA2 as Activator in Liver CellsFunction of alternative splicing
P50
Q24322737-CA6993A6-426A-47E9-A736-D10E460CA208Q28537678-64519E60-FC67-4468-B0E4-CE63DE7C3BB6Q36920326-57332CD8-51DE-4EFB-ACD7-FB1836AD9EAEQ37948566-71CEB24A-2561-49A1-8BFE-2646B5259EE0Q38733639-2193AB27-B473-4A33-8F37-DE329716A271Q38977968-6D99A89E-82D0-453A-B10F-752C4BB20635Q39016007-FA214CEB-B81C-4306-937B-575D0B47364DQ39283327-94555C09-4BDA-4324-8546-F868A5AB3142Q39297889-CABB8182-3060-4955-AB86-B1211E01E84FQ39841343-704F29F4-64EA-4421-81FF-8709090CFDD2Q41189004-7ADA1125-5F7C-4604-9AF0-AAC81D87BC82Q43295992-9A9B2016-C33E-4700-B397-262A032E3410Q44586838-C38DAFC1-C36E-4A49-82E5-45E23287463AQ51199503-B3AD1836-0A6D-4395-80CC-1E41E9AB35F4Q52942913-9F51612F-5B26-416B-9BB2-EF0803EE9585Q56866596-D6AF4908-9006-4D60-BCA6-B7EE1E58D54FQ59474628-23ECF841-12CE-4FC5-85A3-503006F811B9Q64254450-5EEB5353-DF43-42E3-A12E-BBE728839D86Q84837505-91FDE9B1-4328-4D2C-A5CB-DE9D119F4B7F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Convertini
@ast
Paolo Convertini
@en
Paolo Convertini
@es
Paolo Convertini
@it
Paolo Convertini
@nl
Paolo Convertini
@sl
type
label
Paolo Convertini
@ast
Paolo Convertini
@en
Paolo Convertini
@es
Paolo Convertini
@it
Paolo Convertini
@nl
Paolo Convertini
@sl
prefLabel
Paolo Convertini
@ast
Paolo Convertini
@en
Paolo Convertini
@es
Paolo Convertini
@it
Paolo Convertini
@nl
Paolo Convertini
@sl
P106
P1153
26645828000
P21
P31
P496
0000-0001-7250-0678